Results of the head-to-head TEAMMATE trial show the combination of everolimus and low-dose tacrolimus can be considered an alternative to MMF plus tacrolimus in pediatric heart transplant.
Nivolumab instead of brentuximab added onto chemotherapy is suggested as the new standard of care, based on results from the largest Hodgkin lymphoma study in National Clinical Trials Network history.
New data published in NEJM suggest that a high-dose trivalent vaccine offers better protection for kids who receive HSCT than a standard-dose quadrivalent vaccine.
The increased incidence of keratinocyte carcinomas in pediatric transplant recipients is "really high, so we definitely know there s risk there," according to one of the study investigators.